OOIR: Observatory of International Research

Papers

(The H4-Index of Oncologist is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino	174
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model	108
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma	101
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites	94
Calls to action on lung cancer management and research	76
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer	75
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary	64
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs	60
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy	59
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study	59
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)	54
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis	50
The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer	47
IUC23530-78 Diagnostic value, safety, and patient-reported outcomes of total free-hand LATP biopsy technique	43
IUC24430-78 Lesion-level meta-diagnostic of cognitive vs fusion MRI-targeted biopsy in PCa: PRECISION-2 insights	42
IUC24025-78 Early results of moderate hypofractionated radiotherapy implementation for localized prostate cancer patients in Vietnam	41
First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity	40
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer	40
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities	39
GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1	38
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer	38
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma	37
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis	37
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy	36
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review	35

ALK-positive adult histiocytosis with a TFG-ALKfusion gene	34
A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada	34
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management	34
Contextualizing results of randomized trials in smoldering myeloma	34
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland	34
Classification of NK-large granular lymphocytic leukemia by CD56 expression	33
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay	33
Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes	32
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)	32
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy	32
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events	32